title: [Advances and limitations of liver transplantation in Germany].
abstract: Orthotopic liver transplantation (OLT) is now an established therapy for end stage liver disease as well as acute liver failure. Improvements in surgical techniques, meticolous selection of transplant candidates and advances in immunosuppression have markedly increased patient and graft survial. The demand for organ grafts has continuously increased. Living donor organ transplantation omits the problem of organ shortage with prolonged waiting times for OLT and the likelihood of disease progression especially in tumor patients. Advanced liver disease related to chronic viral hepatitis is one of the primary indications for OLT worldwide. Combination therapy with hepatitis B immunoglobulin and lamivudine has been widely adopted as an effective prophylactic treatment regimen against recurrent HBV infection. Reinfection of the allograft is obligate in viremic post transplant patients with HCV infection. However the use of pegylated interferon in combination with ribavirin holds promise for delaying rapid progression of HCV infection in the allograft and the need for retransplantation. Recurrence of PBC, PSC and autoimmune hepatitis affects between 20 % and 30 % grafts at 10 years but appears to have little impact on long-term graft function and survival. In patients with hepatocellular carcinoma fulfilling strict selection criteria for OLT, 5 year survival rates of approximately 75% have been reported.
authors.affiliation: Abteilung für Allgemein- und Transplantations-chirurgie, Universitätsklinikum Essen, Germany.
authors.forename: S
authors.initials: S
authors.lastname: Beckebaum
authors.forename: V R
authors.initials: VR
authors.lastname: Cicinnati
authors.forename: C E
authors.initials: CE
authors.lastname: Broelsch
mesh_terms: D000998:Antiviral Agents / Q000627:therapeutic use; D005858:Germany; D019694:Hepatitis B, Chronic / Q000188:drug therapy / Q000517:prevention & control / Q000601:surgery; D006801:Humans; D007165:Immunosuppression Therapy / Q000379:methods; D017093:Liver Failure / Q000601:surgery*; D016031:Liver Transplantation / Q000009:adverse effects / Q000276:immunology / Q000379:methods / Q000639:trends*; D014019:Tissue Donors / Q000706:statistics & numerical data; D014850:Waiting Lists
chemical_list: D000998:Antiviral Agents